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Synovial sarcomas are rare soft tissue malignancies that most commonly affect theextremities in the vicinity of large joints. These malignancies typically occur inadolescents and young adults between the ages of 15 and 40 years.1,2 Historicallythey are believed to originate from primitive pluripotent mesenchyme capable of
synovial differentiation. This belief is consistent with the malignancy’s origin from sites
devoid of normal synovium, such as the pleural cavity. A variety of pleural cavity sarcomas
have been described, including liposarcoma,3 chondrosarcoma,4 osteosarcoma,5 and malig-
nant schwannoma.6 Pleural synovial sarcoma, however, is a much rarer entity. In fact, pleural
synovial sarcoma was first described only 6 years ago7 and has not yet been reported in the
surgical literature.
Because of its rarity, pleural synovial sarcoma is often mistaken for the histologically
similar malignant mesothelioma, the most common of the pleural neoplasms. This is a critical
distinction, because synovial sarcoma may be extremely aggressive. Studies in the last 10
years have shown it to be extremely sensitive to ifosfamide-based chemotherapy, and survival
of patients with synovial sarcoma has recently increased with chemotherapy, with 5-year
survivals now as high as 57%.8-10
In this report, we describe 3 cases of synovial sarcoma of the pleura. Clinical findings are
correlated with pathologic features, including immunohistochemical stains and fluorescence
in situ hybridization (FISH) for the identification of the diagnostic chromosomal transloca-
tion, t(X;18)(p11.2;q11.2). This delineation of the clinical and pathologic aspects of this rare,
newly recognized tumor should increase awareness among the surgical community.
Methods
Patients and specimens. Institutional review board approval was obtained for our study.
To identify potential cases of monophasic or biphasic synovial sarcoma of the pleura, we
searched the primary and consultation files of the department of pathology at Fairview-
University Medical Center in Minneapolis. All pertinent clinical, radiologic, and pathologic
data, including hematoxylin and eosin–stained slides, were reviewed in all cases.
Immunohistochemical methods. For identified cases of synovial sarcoma, we performed
immunohistochemical studies on representative tissue from paraffin sections. We used the
avidin-biotin complex method and commercially available antibodies as follows: pankeratin
(monoclonal MNF-116, at a dilution of 1:50; DAKO Corporation, Carpinteria, Calif), S100
protein (polyclonal, at a dilution of 1:600; DAKO); and epithelial membrane antigen
(monoclonal E29, at a dilution of 1:10; DAKO). Negative and positive control preparations
were stained in parallel.
Fluorescence in situ hybridization. For identified cases of synovial sarcoma, we per-
formed FISH analysis on interphase nuclei isolated from formalin-fixed, paraffin-embedded
tissue. Nuclei were extracted from paraffin-embedded 50-m tissue sections as described by
Kuchinka and colleagues.11 In brief, the sections were deparaffinized in xylene twice for 5
minutes each time and in ethanol twice for 5 minutes each time. Digestion was performed
with collagenase XI (Sigma Chemical Co, St Louis, Mo) for 2 hours, followed by 0.05%
trypsin and ethylenediaminetetraacetic acid (Life Technologies, Inc, Rockville, Md) for 30
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minutes at 37°C. The cells were spread on positively charged
slides, baked for 2 hours at 50°C, and treated with 30% sodium
bisulfite pretreatment solution (Oncor, Gaithersburg, Md) for 10
minutes, followed by digestion in 250-g/mL proteinase K (On-
cor) for 10 to 15 minutes at 45°C.
For the detection of t(X;18), we used FISH probes for the
chromosome X pericentromeric region and for a region within 1
megabase telomeric to the SYT locus on chromosome 18. The
chromosome X probe was obtained commercially from Vysis
(CEPX; Vysis Inc, Downers Grove, Ill) and was composed of 
satellite DNA sequences from the pericentromeric region directly
labeled with Spectrum Orange. The chromosome 18 probe was
CEPH YAC clone 770c4 (Research Genetics, Huntsville, Ala) that
was biotinylated by random octamer priming. Probes and extracted
nuclei were denatured simultaneously on a HYBrite slide warmer
(Vysis), followed by hybridization at 37°C and stringency washing
in 50% formamide and 2 SSC* for 15 minutes and 2 SSC for
8 minutes at 42°C. Detection of the biotinylated probe was with
fluorescein isothiocyanate–conjugated avidin (Oncor).
At least 30 cells with strong, discrete FISH signals were ana-
lyzed per case. A structural rearrangement between chromosomes
X and 18 was defined as colocalization of the YAC770c4 (fluo-
rescein isothiocyanate conjugate) and CEPX (spectrum orange)
signals no further than a probe signal diameter away from each
other in most cells analyzed.
Results
Clinical data. Clinical data are summarized briefly in Table 1.
PATIENT 1. This patient was a 39-year-old man who was seen
with progressive dyspnea and a pleurally based mass thought to be
clinically consistent with diffuse malignant mesothelioma (Figure
1). Thoracoscopic biopsy was interpreted as malignant mesotheli-
oma, sarcomatous type. The patient subsequently underwent an
uncomplicated left extrapleural pneumonectomy. At the time of
surgery, the pleural tumor was noted to peel off the chest wall
surface with ease, as opposed to the usual tenacious adherence that
sarcomatous mesotheliomas exhibit. After the operation, the pa-
tient received full hemithoracic and mediastinal irradiation.
Four years later, the patient noted a rapidly enlarging left
lumbar paraspinous muscle mass. Computed tomography (CT)
revealed a mass within the left paraspinous muscle, contiguous
with nearby ribs but without involvement of the vertebral body or
transverse process. After negative results of bone scan, the mass
(along with associated muscle, skin, and ribs) was resected. The
final pathologic diagnosis of the mass was read as synovial cell
sarcoma, prompting review of the original pleural tumor. After this
review, it was determined in retrospect that the patient indeed had
a pleural synovial cell sarcoma and that the muscle mass repre-
sented metastatic disease.
One year after resection of the muscle mass (5 years after the
extrapleural pneumonectomy), routine chest CT revealed 30 new
discrete nodules in the remaining right lung and thickened soft
tissue projecting from the chest wall into the left thoracic cavity.
CT-guided biopsy of a right middle lobe nodule was performed,
revealing pathologic findings identical to those of the primary
tumor. Treatment with doxorubicin chemotherapy led to dramatic
reduction in the number of pulmonary nodules, from 30 to 6.
However, a colopleural fistula to the left pleural space (pneumo-
nectomy side) developed. Despite successful surgical repair, the
patient died of the debilitating effects of chemotherapy and sur-
gery.
PATIENT 2. This patient was a previously healthy 23-year-old
woman whose initial evaluation was for a symptomatic left chest
wall lesion. After biopsy, she underwent surgical resection of this
chest wall mass (3  9 cm); the pathologic findings were consis-
tent with synovial sarcoma. Two years after this resection, dyspnea
and a left pleural effusion developed. Evaluation identified a left
pleural mass, which was then widely resected through a left
thoracotomy. Pathologic analysis of this specimen identified this
tumor as mesothelioma (not synovial sarcoma). After the opera-
tion, the patient received a course of doxorubicin (Adriamycin)
adjuvant chemotherapy. She also received tumor cell immunother-
apy (reinjection with neuraminidase-treated primary tumor cells
after bacille Calmette-Gue´rin vaccination). One year later, she
underwent her second thoracotomy because of a left pleural recur-
rence. The tumor was resected, and the pathologic findings were
consistent with synovial sarcoma. Her next chemotherapy regimen
included dacarbazine, vincristine, and cyclophosphamide. One
year later, she returned with a third recurrence. This was locally
advanced disease involving the diaphragm and the left lobe of the
liver. Because this disease was unresectable, the patient underwent
multiple rounds of chemotherapy. She died 4 years after her initial
evaluation.
PATIENT 3. This patient was a previously healthy 33-year-old
man with right-sided pleuritic pain after an upper respiratory
infection. A chest radiograph demonstrated irregularities at the
surface of the right hemidiaphragm. Chest CT demonstrated a
large, complex, 10-cm mass in the right infrahilar region, extend-
ing inferiorly to the level of the diaphragm. Right thoracotomy
with en bloc resection of the pleurally based mass and reconstruc-
tion of the right hemidiaphragm with Marlex mesh (Phillips Pe-
troleum Company, Bartlesville, Okla) were performed. The patient
had an uneventful postoperative course and received no adjuvant
therapy. Currently, he is alive and doing well, without evidence of
recurrent disease at 5 years.
Pathologic data* Saline sodium citrate.
TABLE 1. Clinical and pathological findings
Patient
(age, sex) Histology Pankeratin EMA S100
t(X;18)
by FISH
Status and length of
follow-up
1, (39 y, M) Monophasic Positive Positive Negative Negative Dead, 8 y
2, (23 y, F) Monophasic Positive Positive Negative Positive Dead, 4 y
3, (33 y, M) Biphasic Positive Positive Negative Indeterminate Alive, 5 y
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GROSS EXAMINATION. In case 1, an extrapleural pneumonec-
tomy showed a multifocal tumor between the visceral and parietal
pleura. The largest nodule, near the diaphragm, measured 16 cm in
greatest dimension. In case 2, the tumor resection was piecemeal,
precluding precise measurement. In case 3, the gross specimen
consisted of a 16-cm multilobular, solid, pale tan tumor densely
adherent to the diaphragm.
HISTOLOGIC EXAMINATION. In both patients 1 and 2, the tumors
had a monophasic histologic appearance. In patient 1, the tumor
cells were plump, spindle-shaped, and arranged in short fascicles,
typical of the classic monophasic variant (Figure 2). In patient 2,
the tumor cells were round, with a high nucleus-to-cytoplasm ratio,
and the fascicular architecture was not prominent (Figure 3); thus
the tumor would be classified as a poorly differentiated variant.12 In
patient 3, the tumor was biphasic, with glandular epithelium inter-
spersed among the spindle-shaped cells (Figure 4).
IMMUNOHISTOCHEMICAL ANALYSIS. In patients 1 and 3, pankera-
tin and epithelial membrane antigen showed diffuse immunoreac-
tivity. In patient 2, there was rare focal immunoreactivity. S100
staining was negative in all cases.
FLUORESCENCE IN SITU HYBRIDIZATION. In patient 1, the tumor
was negative for t(X;18). In patient 2, it was positive (Figure 5).
The probes did not hybridize in patient 3, precluding FISH anal-
ysis.
Discussion
Synovial sarcoma involving the pleura was initially recognized
only 6 years ago.7 More cases will no doubt be diagnosed in the
future, thanks to increasing awareness of this entity and increasing
application of adjunctive diagnostic tools. Clearly, surgeons must
be able to recognize pleural synovial sarcoma. The 3 cases re-
ported here represent the first series of pleural synovial sarcomas
reported in the surgical literature.
Because of the rarity of pleural synovial sarcoma and its
similarity (clinical and histologic) to other pleural neoplasms,
particularly sarcomatous mesothelioma, diagnosis is often diffi-
cult. In the series of 5 primary pleural synovial sarcomas reported
by Gaertner and associates,7 the original diagnoses were malignant
mesothelioma, fibrosarcoma, and pulmonary blastoma. In our se-
ries, cases 1 and 2 were diagnosed at one point as malignant
mesothelioma. After resection, both tumors recurred. In retrospect,
the misdiagnosis of malignant sarcomatous mesothelioma in case
1 should have been suspected during follow-up. The patient’s
relatively young age and prolonged clinical course (8 years),
makes the diagnosis of sarcomatous mesothelioma most unlikely.
Sarcomatous mesothelioma typically presents at a later age (40-70
years old) with diffuse pleural thickening, and the median survival
is 4 to 12 months after diagnosis.13 Patients with synovial sarcoma
also have an aggressive clinical course but tend to survive longer
than those with mesothelioma.7 As evidenced by patient 1, syno-
vial sarcoma typically recurs after resection and is diagnosed by
combining the clinical presentation with pathologic analysis.
Histologically, synovial sarcomas are either monophasic (con-
sisting entirely of spindle cells) or biphasic (both epithelial and
spindle cells). The biphasic tumors are more distinctive and thus
more easily distinguished from other pleural sarcomas. In our
series, case 3 represented a biphasic synovial sarcoma for which a
definitive diagnosis was made on the initial biopsy. The monopha-
sic variant is composed of spindle cells histologically similar to
sarcoma and sarcomatous mesothelioma. Ancillary tests, such as
Figure 1. Pleural monophasic synovial sarcoma. Selected sections of conventional CT scan of chest from patient
1 showing large peripheral homogeneous soft tissue mass growing within pleural cavity.
Figure 2. Synovial sarcoma, monophasic type. Hematoxylin and
eosin–stained section from patient 1 depicting monophasic sy-
novial sarcoma (original magnification 40). Tumor cells are
plump, spindle-shaped, and arranged in short fascicles, typical of
classic monophasic variant.
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immunohistochemical or cytogenetic studies are helpful to confirm
diagnosis.
Immunohistochemical findings that distinguish synovial sar-
coma from other pleural sarcomas include positive staining for
cytokeratin and epithelial membrane antigen. Synovial sarcomas
lack staining for neural (S100) and smooth muscle (desmin,
smooth muscle actin) markers.14 This staining pattern is similar to
that of sarcomatous mesothelioma, limiting its usefulness. The
epithelial marker BerEp4 may help to distinguish biphasic syno-
vial sarcoma from malignant mesothelioma, because it consistently
stains biphasic synovial sarcoma, but is only focally positive in
Figure 4. Synovial sarcoma, biphasic type. Hematoxylin and eo-
sin–stained section from patient 3. Tumor is biphasic and shows
glandular epithelium interspersed among spindle-shaped cells
(original magnification 40).
Figure 5. FISH analysis. A, Patient 1, interphase nucleus with
normal hybridization pattern for CEPX (orange) and YAC770c4
(green). B, Patient 2, interphase nucleus with abnormal hybrid-
ization pattern of colocalized YAC770c4 (green) and CEPX (or-
ange) signals indicating 5(X;18).
Figure 3. Synovial sarcoma, monophasic type. Hematoxylin and eosin–stained section from patient 2 depicting
poorly differentiated monophasic synovial sarcoma with round cells showing high nucleus-to-cytoplasm ratio and
absence of fascicular growth (original magnification 40).
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some mesotheliomas. However, it is less useful for distinguishing
between mesothelioma and monophasic synovial sarcoma, which
also stains variably with BerEp4.14
The chromosomal translocation t(X;18)(p11.2;q11.2) has been
found in more than 90% of synovial sarcomas, regardless of
histologic subtype.12,15-17 This translocation results in the fusion of
the SYT gene on chromosome 18 to either the SSX1 or SSX2 gene
on chromosome X.18 Several techniques can be used to identify the
translocation or fusion transcript, including conventional cytoge-
netic analysis, molecular cytogenetic analysis (FISH), and reverse
transcriptase–polymerase chain reaction assay.17-20 Recently,
Aubry and colleagues21 reported 5 cases of pleural synovial sar-
coma with this confirmed genetic rearrangement. In our series,
case 2 represents a poorly differentiated tumor in which diagnosis
was significantly aided by the positive FISH findings.
Optimal treatment for pleural synovial sarcoma has not been
defined. Multimodal therapy of surgery, chemotherapy, and radi-
ation has been used.7 Recurrences are likely and may be treated
with further resections. In the extremities, synovial sarcoma has a
notable sensitivity to chemotherapy, especially ifosfamide and
doxorubicin.22 In our series, patient 1 showed a dramatic response
to doxorubicin, with a reduction in the number of pulmonary
nodules from 30 to 6. Thus if diagnosed correctly, synovial sar-
coma may respond to specific chemotherapeutic agents.
As our 3 cases of pleural synovial sarcoma demonstrate, cor-
rect, timely diagnosis of this exceptionally uncommon tumor is
essential for optimal therapy and survival.
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